Venetoclax Plus Hypomethylating Agents and Subcutaneous Cytarabine for CEBPA-Mutated AML

Inclusion Criteria: * Patients can participate in this study only if they meet all the following enrollment criteria: 1. Aged over 18 years, male, or female who is neither pregnant nor lactating; 2. Newly diagnosed acute myeloid leukemia (AML) with CEBPA mutation; 3. ECOG performance status ≤ Grade 3; 4. Capable of understanding and willing to participate in the study, and able to sign the informed consent form; 5. Patients are judged as "unfit" according to the Ferrara criteria. A patient is considered "unfit" if they meet at least one of the following criteria: * Advanced age: \> 75 years old; * Presence of severe underlying comorbidities involving the heart, lungs, kidneys, or liver; ③ Presence of active infection unresponsive to anti-infective treatment; * Presence of cognitive impairment; ⑤ Poor performance status (persistent ECOG score ≥ Grade 3); ⑥ Other comorbidities judged by the investigator to make the patient unfit for intensive chemotherapy. Exclusion Criteria: * Patients are not suitable for participating in this study if they meet any of the following exclusion criteria: 1. Pregnant or lactating women; 2. Previous receipt of chemotherapy or targeted drug therapy for leukemia before the study treatment (except oral hydroxyurea used to reduce white blood cell count and/or leukapheresis); 3. As known to the participant and the investigator, the participant may be unable to complete all study visits or procedures required by the study protocol (including follow-up visits) and/or unable to comply with the required study procedures; 4. Other conditions judged by the investigator to make the patient unfit for participating in this study.